Proteomics and metabolomics profiling reveal panels of circulating diagnostic biomarkers and molecular subtypes in stable COPD

Zili Zhang, Jian Wang, Yuanyuan Li, Fei Liu, Lingdan Chen, Shunping He, Fanjie Lin, Xinguang Wei, Yaowei Fang, Qiongqiong Li, Juntuo Zhou, Wenju Lu. Respir Res. 2023 Mar 11;24(1):73.

Observational studyHumans

Design

Observational study

Subjects

40 patients with stable advanced COPD and 40 controls, plus 29 COPD and 31 controls for validation

Dose used in the study

No palmitoylethanolamide was given; blood levels were measured

Duration

Not stated in the abstract

What was measured

Plasma proteomics and metabolomics; diagnostic accuracy of biomarker panels by ROC analysis; molecular subtyping

What the authors reported

The study found:

• A panel of theophylline, palmitoylethanolamide, hypoxanthine and cadherin 5 diagnosed advanced COPD with an area under the ROC curve of 0.98, sensitivity 0.94 and specificity 0.95.
• Proteomics separated three COPD subtypes.
• Theophylline and CDH5 were raised only in advanced, not mild, COPD.

Limits of this study

An observational biomarker study; PEA was a marker, not a treatment. Small cohorts from one centre. The authors declare no conflict of interest.

Source

PubMed 36899372 · doi:10.1186/s12931-023-02349-x

Entry checked against the abstract on PubMed on 2026-09-22. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.